A subgroup analysis of a Phase 3 trial involving patients with type 2 diabetes mellitus and hypertriglyceridemia revealed that pemafibrate decreased the HOMA‐IR level and improved insulin resistance through an increase in the serum fibroblast growth factor 21 level.31 Here, FGF21 is linked to hypertriglyceridemia.